CytoSorbents Appoints Dr. Rainer Kosanke as European Director of Scientific Affairs

CytoSorbents Appoints Dr. Rainer Kosanke as European Director of Scientific
Affairs

MONMOUTH JUNCTION, N.J., July 8, 2013 (GLOBE NEWSWIRE) -- CytoSorbents
Corporation (OTCBB:CTSO), a critical care focused company commercializing its
European Union approved CytoSorb® blood filter to treat life-threatening
illnesses in the intensive care unit, announced today that its wholly-owned
subsidiary, CytoSorbents Europe GmbH has appointed Dr. Rainer Kosanke, PhD, as
European Director of Scientific Affairs.

Dr. Kosanke was formerly the Head of Medical Marketing for Germany, Austria,
and Switzerland and Deputy Sales Director at B.R.A.H.M.S AG where he helped to
lead the market introduction and development of the now leading sepsis
biomarker in the world, procalcitonin (also known as PCT), from 2003-2009. PCT
has become the gold standard in Europe to both diagnose bacterial sepsis, and
to help guide the length of antibiotic treatment. In 2009, Thermo Fisher
Scientific acquired B.R.A.H.M.S. AG for $470 million, or 4.5 times 2008
revenue of $105 million, based primarily on the potential worldwide market for
PCT, but also for biomarkers for cardiovascular disease and neurologic
disorders. At Thermo Fisher Scientific, Dr. Kosanke was in charge of
coordinating a number of large randomized controlled clinical trials using PCT
and other sepsis biomarkers under development, with combined target enrollment
of more than 2,800 patients. Dr. Kosanke received his PhD from the
Ernst-Moritz-Arndt University of Greifswald, where he became an Associate
Professor. He has extensive expertise in inflammation, blood coagulation, the
systemic inflammatory response syndrome (SIRS, which includes sepsis), and
biomarkers of sepsis.

At CytoSorbents Europe GmbH, Dr. Kosanke will assume direct responsibility for
the ongoing CytoSorb® Dosing Study that is investigating the safety and
efficacy of longer blood purification treatment in severe sepsis or septic
shock patients with respiratory failure. He will also coordinate the growing
number of investigator-initiated studies, now more than ten, that will use
CytoSorb® in numerous treatment scenarios including sepsis, cardiac surgery,
pancreatitis, acute kidney injury, severe lung injury, liver failure and
others. This includes a recently announced 40 patient randomized controlled
trial investigating the ability of CytoSorb® to reduce key cytokines during
and after elective cardiopulmonary bypass (CPB) surgery, when used in parallel
to the CPB circuit, at the Medical University of Vienna. Dr. Kosanke will also
be responsible for establishing an international patient registry for
CytoSorb® treatments.

Dr. Christian Steiner, Vice President of Sales and Marketing of CytoSorbents
Corporation, and a Managing Director of CytoSorbents Europe GmbH, stated, "We
are pleased to welcome Rainer to the CytoSorbents Europe team. His deep
understanding of the cytokine-driven inflammatory cascade, and how it impacts
organ injury in life-threatening illnesses combined with his experience
introducing a sepsis diagnostic tool to key opinion leaders in our direct
sales territory is a perfect fit for our company. In addition, his background
in managing clinical trials at Thermo Fisher will be invaluable as we expand
the clinical experience with CytoSorb®."

Dr. Kosanke commented, "New technologies offer an excellent opportunity to
improve the treatment of critically ill patients. For example, the development
of new diagnostics such as PCT has led to a more rapid diagnosis of sepsis
with improved antibiotics management. Now we need to focus on developing
better treatments to improve patient outcomes in sepsis and other serious
illnesses. In Germany alone, more than 60,000 patients die each year from
complications of sepsis."

Dr. Kosanke continued, "I believe that the elimination of inflammatory
substances such as cytokines with CytoSorb® can substantially improve the
treatment of patients with SIRS, and is the right approach to help reduce
organ dysfunction and failure. I am excited to have the opportunity to
contribute to this innovative company, and advance CytoSorb® therapy in
Europe."

About CytoSorbents Corporation

CytoSorbents is a critical care-focused therapeutic device company using blood
purification to modulate the immune system - with the goal of preventing or
treating multiple organ failure in life-threatening illnesses. Organ failure
is the cause of nearly half of all deaths in the intensive care unit, with
little to improve clinical outcome. CytoSorb®, the Company's flagship product,
is approved in the European Union as a safe and effective extracorporeal
cytokine filter, designed to reduce the "cytokine storm" that could otherwise
cause massive inflammation, organ failure and death in common critical
illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis.
These are conditions where the mortality is extremely high, yet no effective
treatments exist. CytoSorbents' purification technologies are based on
biocompatible, highly porous polymer beads that can actively remove toxic
substances from blood and other bodily fluids by pore capture and surface
adsorption. CytoSorbents has numerous products under development based upon
this unique blood purification technology, protected by 32 issued US patents
and multiple applications pending, including HemoDefend™, ContrastSorb,
DrugSorb, and others. Additional information is available for download on the
Company's website: http://www.cytosorbents.com

Forward-Looking Statements

This press release includes forward-looking statements intended to qualify for
the safe harbor from liability established by the Private Securities
Litigation Reform Act of 1995. Forward-looking statements in this press
release are not promises or guarantees and are subject to risks and
uncertainties that could cause our actual results to differ materially from
those anticipated. These statements are based on management's current
expectations and assumptions and are naturally subject to uncertainty and
changes in circumstances. We caution you not to place undue reliance upon any
such forward-looking statements. Actual results may differ materially from
those expressed or implied by the statements herein. Risk factors are detailed
in the Company's Form 10-K filed with the SEC on April 3, 2013, which is
available at http://www.sec.gov.

CONTACT: Company Contact:
         CytoSorbents Corporation
         Dr. Phillip Chan
         Chief Executive Officer
         (732) 329-8885 ext. *823
         pchan@cytosorbents.com
        
         Investor Contact:
         Alliance Advisors, LLC
         Alan Sheinwald
         (914) 669-0222
         asheinwald@allianceadvisors.net
        
         Valter Pinto
         (914) 669-0222 x201
         valter@allianceadvisors.net
        
         Media Contact:
         JQA Partners
         Jules Abraham
         (917) 885-7378
         jabraham@jqapartners.com
 
Press spacebar to pause and continue. Press esc to stop.